1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc.

LIXTW
Lixte Biotechnology Holdings, Inc.US flagNASDAQ Capital Market
0.02
USD
+0.02
- -
100,551.00Market Cap
Lixte Biotechnology Holdings, Inc.
LIXTW
(NASDAQ Capital Market)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-1,323.21
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-2
-4
-1
-3
-3
-2
-2
-2
-2
-3
-7
-6
-5
-4
-6
-7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-1,426.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
2
- -
1
- -
- -
- -
- -
1
4
2
5
5
5
4
1
4
2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
2
- -
1
- -
- -
- -
- -
1
4
2
5
5
5
4
1
11
9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
3
2
- -
Shares Outstanding
6
9
12
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
5
5
3
Cash, Cash Equivalents & STI
5
5
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
183.82%
225.31%
1,225.11%
Free Cash Flow
7.57%
13.9%
-2.97%
Net Income, GAAP
14.43%
23.71%
67.58%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
-3,553.65%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
RenovoRx, Inc. (RNXT)
Biohit Oyj (BIOBV.HE)
Tetra Bio-Pharma Inc. (TBPMF)
scPharmaceuticals Inc. (SCPH)
Wuhan YZY Biopharma Co Ltd (2496.HK)
Cassiopea S.p.A. (SKIN.SW)
Business
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT, LIXTW) is a clinical-stage pharmaceutical company that develops protein phosphatase 2A (PP2A) inhibitors for oncology treatments; its lead product candidate, LB-100, enhances the efficacy of chemotherapy and immunotherapy by promoting neoantigen production, cytokine release, T-cell proliferation, and disruption of cancer cell DNA repair mechanisms; LB-100 advances in phase 1b/2 clinical trials for ovarian clear cell carcinoma combined with dostarlimab, microsatellite stable metastatic colon cancer combined with atezolizumab, and advanced soft tissue sarcoma with standard chemotherapy. The company, founded in 2005 and headquartered in Pasadena, California, targets solid tumors with unmet needs through its proprietary, patented platform with no known direct competitors. Recent developments include the November 2025 acquisition of Liora Technologies' proprietary LiGHT System proton therapy platform, establishing Liora as a wholly owned subsidiary to enter the radiotherapy segment and pursue scalable high-precision cancer treatments; a September 2025 strategic purchase of 10.5 Bitcoin and 300 Ethereum for $2.6 million to diversify treasury holdings up to 50%; two financings raising $6.5 million and Nasdaq compliance regain in August 2025; appointment of two new board members and relocation of corporate headquarters to Boca Raton, Florida, in September 2025; and confirmation of advanced acquisition negotiations for complementary oncology assets.